Navigation Links
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
Date:12/4/2012

The population of the United States is getting older, due not only to aging boomers but also to a four-year increase in life expectancy from 1990 to 2010. An aging population means increased diagnosis of prostate cancer. Statistically, the older the patient at time of diagnosis, the more aggressive the disease and also the less well the patient is likely to tolerate traditional chemotherapies. In sum, we have more, aggressive prostate cancer that can't be targeted by traditional treatments.

Members of the University of Colorado Cancer Center recently published a review in the journal Drugs and Aging describing the modern state of prostate cancer care examining not only new drugs but entirely new classes of drugs that may be effective and well-tolerated in these aging patients.

"For patients with advanced prostate cancer, there are more options than ever before. But with more options comes a more complex decision tree in choosing appropriate therapies," says Elizabeth Kessler, MD, oncology fellow at the University of Colorado Cancer Center and the review's lead author.

First among these options are targeted therapies. Modern targeted therapies are able to selectively kill cancer cells as opposed to accepting high collateral damage in healthy tissue and so frequently have fewer side effects than traditional chemotherapies. (And are thus better tolerated by elderly patients.)

"These are drugs like abiraterone and enzalutamide that have been approved for use in late stage prostate cancer and are now being evaluated for earlier use," Kessler says. Prostate cancer generally depends on androgen hormones like testosterone to survive and grow even after traditional hormone blockade, the body continues to produce minute amounts of testosterone and even this little bit is enough to drive prostate cancer. By completely removing the body's ability to produce testosterone or the cancer's ability to use it, these drugs break the messaging chain that tells prostate cancer to grow. CU Cancer Center researchers have played an important role in the clinical development of both of these drugs.

Researchers are also looking for additional, molecular drivers of prostate cancer, perhaps for example insulin growth factor.

"We're also exploring the use of targeted kinase inhibitors," Kessler says. For example, the drug known as XL184 by Exelixis is currently in clinical trials to target MET and VEGF, "and appears to show effect against bone lesions, the most common location of prostate cancer metastasis," Kessler says.

"Another promising strategy to treat metastatic prostate cancer is immunotherapy," Kessler says. In immunotherapy, drugs, devices or treatments are used to sensitize the body's immune system to attack cancer cells boosting the body's ability to clear itself of cancer. For example, the drug Sipuleucel-T was approved by the FDA in 2010 for treatment of metastatic prostate cancer "but it requires blood to be removed, treated, and reinfused," Kessler says a procedure that can only be accomplished by shipping the patient's blood to facilities in other cities before reinfusing it here. Second generation prostate cancer immunotherapies including Prostvac are in development or clinical trials, including an open trial at the CU Cancer Center.

Finally, researchers are exploring ultra-precise targeting of radiation that rides along with drugs that attach to bone metastases and affects only the tumor cells in the immediate areas of attachment. "One of these drugs is Alpharadin," Kessler says, "which goes only shallowly into bone and so targets lesions without stopping the production of bone marrow."

"There has been a major shift in the acceptance of these drugs," Kessler says. "We're learning to reach for them sooner and more frequently in place of traditional chemotherapies."

This shift means that just as boomers pass age 65 the most common time of prostate cancer diagnosis researchers have a handful of new barriers to put in the path of the disease.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Cancer Care Costs Higher in U.S. Than Europe, But Survival Longer
2. Exercise May Help Patients With High Blood Pressure Live Longer
3. Hispanic lung cancer patients tend to live longer than blacks and whites
4. How That Glass of Red Wine Might Help You Live Longer
5. Joggers Live Longer, Study Says
6. Female and younger athletes take longer to overcome concussions
7. Living longer - variability in infection-fighting genes can be a boon for male survival
8. A Little More Education, a Little Longer Life?
9. Females, Young Athletes Take Longer to Get Over Concussions
10. Deep Brain Stimulation May Offer Longer-Term Relief for Parkinsons
11. Fear of Childbirth Linked to Longer Labor, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... , ... On Sunday, September 24, hundreds will gather at Flo Jo Park ... the fastest woman of all time. Flo Jo passed away from complications related ... National Anthem. Mary was a contestant on the 2012 season of America’s Got ...
(Date:9/22/2017)... Plano, TX (PRWEB) , ... September 22, 2017 , ... ... created to strengthen the communities they serve as part of the nationally recognized ‘Agents ... by working closely with nonprofit organizations and community leaders to seek out those who ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... operations and financial setbacks, a senior finds a new lease on life with ... helped thousands of people resolve their problem with unsecured debt. The senior is ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from ... in Educational Leadership and Administration at St. Thomas University in Miami, Florida, was ...
(Date:9/22/2017)... ... ... Pullano Law Offices, a Chicago personal injury law firm, is pleased to ... as President of the North Suburban Bar Association for 2017-2018. Mr. Pullano was installed ... NSBA at the North Shore Country Club in Glenview, IL, on September 13, 2017. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017 ... coming to Washington DC ... Tuesday, September 12 th – Monday, September 18 th .The Brain ... MRI brain scans to the public.Where:  BTF,s Mobile ... 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road ...
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
Breaking Medicine Technology: